Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
06:20am, Wednesday, 28'th Jul 2021
LONDON and SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a Joint Procurement Agreement
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
04:05pm, Thursday, 22'nd Jul 2021
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter e
Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study
12:26pm, Friday, 16'th Jul 2021
Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.
Vir Biotechnology Starts Dosing In Mid-Stage Hepatitis B Trial With Combination Therapy
09:46am, Thursday, 15'th Jul 2021
Vir Biotechnology Inc (NASDAQ: VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434 to treat patients with chronic hepatitis B virus (HBV) in
These COVID Therapies Appear to Be the Best and Worst at Treating New Variants
06:04am, Saturday, 03'rd Jul 2021
Here's how several leading COVID-19 antibody therapies compare based on pre-clinical testing.
GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know
06:10am, Thursday, 01'st Jul 2021
The sample size was small, but the results were impressive.
Vir Biotech's HBV Candidates Show Positive Safety Profiles
03:02pm, Friday, 25'th Jun 2021
Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection.
– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel HBV therapies administrated as monotherapy or in combination with other agents –
Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death
10:31am, Tuesday, 22'nd Jun 2021
Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make
GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients
11:41am, Monday, 21'st Jun 2021
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating sotrovimab in high-risk adult outpatients
Vir, GSK say new data confirms their COVID-19 treatment can reduce hospitalization and death
07:28am, Monday, 21'st Jun 2021
Shares of Vir Biotechnology Inc. gained 1.4% in premarket trading on Monday after the company said the COVID-19 antibody treatment it developed with GlaxoSmithKline cut the risk of hospitalization and
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
07:06am, Monday, 21'st Jun 2021
– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progre
3 Top Biotech Picks for June
06:00am, Saturday, 19'th Jun 2021
Coronavirus players may deliver strong returns well into the future.
Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
04:05pm, Wednesday, 02'nd Jun 2021
SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat
15 Words From Vir Biotechnology's CEO May Mean Market Dominance
06:00am, Wednesday, 02'nd Jun 2021
Vir's antibody treatment is addressing one of the biggest COVID challenges.
